Obesity

Why weight returns fast after stopping obesity drugs? Homeostasis explained

Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected

Stopping Ozempic or Mounjaro? The weight may come back faster than you think

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

How eggs can help you come off Wegovy, solve problem of weight regain

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

GLP-1 launches inject over 2x rise in weight-loss market sales in 2025

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

Obesity drugs to be new growth engine for pharma industry: Sun Pharma

Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry, according to Sun Pharma Managing Director Kirti Ganorkar. Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production. India, known for its generic drug industry, is rapidly transforming into a major hub for the global weight management industry, amid rapid increase in obesity-led disease burden. "Improving access to GLP-1 treatments in the coming years will be a key driver for the Indian pharmaceutical industry, helping address the growing burden of lifestyle diseases such as obesity and diabetes," Ganorkar told PTI. Combined with AI-enabled digital tools for early disease detection and monitoring, and personalised medicine choices, the industry will continue to drive innovation that supports accessibility, affordability, and ..

How 2025 marked a turning point for health science and innovation

From GLP-1 drugs and personalised cancer vaccines to longevity experiments and regenerative therapies, 2025 marked a year when scientific breakthroughs reshaped healthcare and medicine

Eli Lilly, Novo Nordisk compete for lead in India's obesity drug market

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Novo gets US nod for Wegovy pill, eyes January launch in obesity market

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

Emcure targets pan-India obesity market with Poviztra semaglutide

As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Harvard study finds gut-liver link that may shape future obesity treatments

A new study shows how gut-produced metabolites influence insulin response and fat metabolism, opening the door to potential future treatments for obesity and type 2 diabetes

Can Ozempic trigger depression or suicidal thoughts? Australia weighs in

Australia has issued a safety alert on GLP-1 drugs after reviewing reports of depression and suicidal thoughts; while there is no proven causal link, regulators want users to stay alert

WHO issues first guidelines backing GLP-1 drugs for obesity management

WHO has issued its first guidelines recommending GLP-1 drugs for long-term obesity treatment in adults, while stressing equitable access, health system readiness and lifestyle support

Metropolis launches GLP-1 monitoring test packages, targets obesity market

Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment

Why alcohol may hit harder for people on GLP-1 drugs like Ozempic, Wegovy

A Yale study suggests GLP-1 drugs like semaglutide slow alcohol breakdown in the liver, raising blood alcohol levels even as they reduce toxic byproducts linked to inflammation and liver damage

Biorad Medisys works on 'pacemaker' for managing diabetes with VNS tech

Pune-based Biorad Medisys is developing an implantable vagus nerve stimulation device that aims to improve insulin balance, regulate hunger, and support obesity care without drugs or chemical compound

Why losing weight is harder than we think, and how evolution has shaped it

Advances in obesity and metabolism research may mean that future therapies can be able to turn down these signals that drive the body back to its original weight, even beyond the treatment period

Did you gain weight in first year of college? Here's the science behind it

A new study finds that college students often misjudge how much they eat, especially in dining halls or social settings, highlighting how environment drives calorie intake and weight gain

Russian teens turn to Molecule, a banned pill with deadly weight-loss risks

Marketed as a herbal weight-loss supplement, Molecule has gone viral on Russian TikTok but contains a banned drug linked to heart attacks, anxiety, and hospitalisations among teenagers